Although ineffective as a monotherapy, when combined with anti–PD-1, anti-CCR2 provided potent antitumor effects in two syngeneic GBM models, suggesting that targeting of CCR2 and PD-1 is a therapeutic combination worth exploring in human GBM patients. Here, CCR2 is linked to glioblastoma.